News | June 11, 2007

Ablation Frontiers Announces CE Mark, Commercial Launch of Novel Cardiac Ablation System

June 12, 2007 - Ablation Frontiers, Inc., developer and manufacturer of three-dimensional catheters for the treatment of atrial fibrillation (AF), announced that it received the CE Mark for its Cardiac Ablation System consisting of a portfolio of anatomical based catheters and a uniquely designed radiofrequency (RF) energy delivery system, for which the company initiated the first commercial use of its Ablation System this year at key international cardiac centers throughout the European Union and other International markets that recognize the CE Mark.

Ablation Frontiers proprietary products are designed to treat all types of atrial fibrillation, including patients with paroxysmal, persistent and the more difficult to treat, permanent AF. The novel catheters effectively treat tissue in the right and/or left atrium through percutaneous access to the heart. Ablation Frontiers, Inc. has developed a toolkit of catheters specifically designed for the atrial anatomy and AF ablation. The catheters are powered by a RF energy source that allows a physician to precisely control the energy and tailor treatment for the individual needs of the patient. Design goals centered on the need to develop a very simple but elegant therapy solution that could greatly reduce procedure times, improve safety and be easily learned by most electrophysiologists. Unlike all other treatment approaches, this technology does not rely on three-dimensional mapping or catheter steering robotics, but the percutaneous cardiac catheters are inserted through a patient’s leg vein and advanced into the right and/or left atrium. Each catheter is designed to map, and using radiofrequency energy, ablate specific target sites through simultaneous selective combinations of multiple electrode channels.

For more information:

Related Content

Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Sponsored Content | Videos | Atrial Fibrillation| May 17, 2017
Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopk
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
The Arctic Front Advance Cardiac CryoAblation Catheter treats atrial fibrillation with pulmonary vein isolation
News | Atrial Fibrillation| April 11, 2017
April 10, 2017 — Medtronic recently announced the first enrollments in the STOP Persistent AF clinical trial.
Overlay Init